FindTrial
Sign In

Accurate diagnosis of prostate cancer based on serum miRNAs

Accurate diagnosis of prostate cancer based on serum miRNAs

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083427
Enrollment
Unknown
Registered
2024-04-24
Start date
2024-04-24
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Gold Standard:Prostate cancer needle biopsy
Index test:Serum miRNA (miR-17-3p,miR-504-3p and miR-6877-5p) levels were detected by qPCR

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients waiting for a prostate biopsy to confirm whether they have prostate cancer

Exclusion criteria

Exclusion criteria: Previous tumor history

Design outcomes

Primary

MeasureTime frame
AUC ;—

Secondary

MeasureTime frame
Accuracy;sensitivity;Specificity;Positive predictive value;Negative predictive value;—

Countries

China

Contacts

Public ContactKewei Xu

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

xukewei@mail.sysu.edu.cn+86 189 2218 2531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026